Vivosim labs inc VIVS.US 總覽分析
VIVS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
VIVS 近期報酬表現
1.52%
Vivosim labs inc
3.56%
同產業平均
1.47%
S&P500
與 VIVS 同產業的標的表現
- IBO Impact biomedical inc價值 -趨勢 2 分波段 4 分籌碼 -股利 1 分查看更多
VIVS 公司資訊
VivoSim Labs, Inc., formerly Organovo Holdings, Inc., is a clinical-stage biotechnology company. The Company is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. It focuses on developing novel treatment approaches in inflammatory bowel disease (IBD). Its proprietary technology is used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.